{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1600"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"The highest dose tested (Total Marrow Irradiation) in which there is no treatment related mortality and none or only one patient experienced dose limited toxicity (DLT) attributable to the study drug(s), when at least six were fully treated at that dose and fully followed for toxicity. The MTD is one dose level below the lowest dose tested in which 2 or more patients experienced DLT attributable to the treatment or there was a treatment related death. At least 6 patients will be treated at the MTD.","groups":[{"description":"See Detailed Description\n\ntotal marrow irradiation: Undergo irradiation escalating according to the following schedule 1000cGy, 1200cGy, 1400cGy, 1600cGy, 1800cGy\n\nmelphalan: Given IV\n\nperipheral blood stem cell transplantation: Undergo transplantation\n\nfilgrastim: Given IV\n\nfluorescence in situ hybridization: Correlative studies\n\ncytogenetic analysis: Correlative studies\n\ncyclophosphamide: Given IV\n\nautologous-autologous tandem hematopoietic stem cell transplantation: Undergo transplantation\n\nlenalidomide: Given orally","id":"OG000","title":"Treatment Arm"}],"paramType":"NUMBER","populationDescription":"All patients enrolled in the dose-finding portion of the study.","reportingStatus":"POSTED","timeFrame":"8 weeks from start of treatment, up to 2 years","title":"Maximum Tolerated Dose (MTD)","type":"PRIMARY","unitOfMeasure":"cGy"}